This year marks the 20th anniversary of the ASCO Genitourinary Cancers. Attendees can look forward to multiple presentations on prostate, urothelial, renal cell, adrenal, and testicular cancers. Cheryl T. Lee, MD, will present the keynote: Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials.
Three general sessions are devoted to prostate cancer. One addresses management options for disease progression after upfront treatment intensification for metastatic hormone sensitive prostate cancer, including sequencing hormonal therapies, prostate specific membrane antigen (PSMA) and radium-223, adding poly ADP-ribose polymerase (PARP) inhibition to androgen receptor targeting, and determining which patients might benefit from stereotactic radiotherapy.
The second looks at emerging evidence in localized and recurrent disease for salvage radiotherapy after biochemical recurrence of prostate cancer following local treatment. Scott E. Eggener, MD, and Martin Gleave, MD, will debate the pros and cons of renaming Gleason 3+3 (Grade Group 1).
The third includes a clinical case panel discussion on whether new imaging, surgical, and radiation therapy techniques can be used to de-escalate prostate cancer treatment, reduce toxicity, and maintain efficacy.
The urothelial carcinoma track includes a general session on optimizing treatment strategies in node-positive disease, e.g., surgery versus radiation therapy. An abstract on using fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement in muscle-invasive bladder cancer (MIBC) in patients enrolled in neoadjuvant therapy trials will be presented.
Another session will address the shortage of drugs for urothelial carcinoma and possible solutions from the perspectives of community oncology, patient advocacy, an oncology research network, and the FDA. A third session in this track will present the role of immunotherapy in advanced urothelial carcinoma.
Two renal cell carcinoma (RCC) general sessions present updates on classification and treatment, one of which addresses RCC with sarcomatoid features or variant histologies. There is also a general session on multidisciplinary management of small cell neuroendocrine tumors.
Clinical trial results are presented in oral abstract sessions. Rapid oral abstract sessions will also provide the presenters with the opportunity to respond to questions as part of moderated panel discussions after presenting their clinical trial results.
Studies with patient-reported outcomes include patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of gonadotropin releasing hormones agonist after radical prostatectomy for advanced prostate cancer; the ACE study, a multi-center prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide; and a three-phase study to develop a HRQoL measure for metastatic RCC.
Artificial intelligence is mentioned in at least one abstract: a multimodal deep learning model integrating histopathology, cell types, and gene expression, is being used to predict clinical outcomes in the S1314-COXEN trial of neoadjuvant chemotherapy for urothelial carcinoma.
In addition to viewing poster sessions, two of which are for trials in progress, meeting registrants can access on-demand sessions on the “best of” journals for urothelial carcinoma, RCC, and prostate cancer, and practice-changing guideline updates for prostate cancer, urothelial carcinoma, renal cell cancer, and testicular cancer.
Dr. Lederman has no conflicts of interest to report.
Illustration by April Brust
